You searched for "Infertility"

220 results found

Mindfulness-based stress reduction as a novel treatment for IC/PBS

Interstitial cystitis / painful bladder syndrome (IC / PBS) is not fully understood and is associated with significant morbidity. The objective of this study was to provide initial data to evaluate mindfulness-based stress reduction (MBSR) as a treatment for IC...

How effective are intravesical therapies for bladder pain syndrome?

The objective of this study was to review the clinical efficacy of currently available products for the intravesical treatment of bladder pain syndrome (BPS) / interstitial cystitis (IC) and to assess their pharmaco-economic impact. Nineteen articles were reviewed, including five...

New senior appointments at The Urology Foundation

The Urology Foundation (TUF) has appointed Rebecca Porta as Chief Executive. An established and experienced charity Chief Executive, Rebecca brings a wealth of experience having held senior roles within some of the UK’s leading health and medical research charities.

Surgery in disorders of sexual development with gender issues

After the initial consensus meeting of 10 years ago on disorders of sex development (DSD) with the introduction of the new terminology and classification there are still abundant controversial issues associated with the management of children with these conditions. This...

Balanitis xerotica obliterans

Balanitis xerotica obliterans (BXO) / lichen sclerosus of the male genitalia is a common cause of acquired phimosis, and was first described by Stuhmer in 1928 [1]. It is described in medical literature as a chronic inflammatory condition of unknown...

IC and risk of CHD

Bladder pain syndrome / interstitial cystitis (BPS/IC) is a chronic, multifactorial and relapsing condition. Aetiology includes: inflammation, allergic, neuropathic, auto immune, vascular factors, etc. This study from Taiwan aimed to investigate the risk of coronary heart disease (CHD) among IC...

New senior appointments at The Urology Foundation

New Chief Executive appointed The Urology Foundation (TUF) has appointed Rebecca Porta as Chief Executive. An established and experienced charity Chief Executive, Rebecca brings a wealth of experience having held senior roles within some of the UK’s leading health and...

The urinary microbiome in IC/BPS: more complicated than we imagined

The concluding statement of this short review states, “the study of the urinary microbiome and its impact on urological disease, including IC/BPS, is in its infancy.” A lot has been said on this subject in recent years, but this, in...

Blaedderwaerc and other names

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would explore the history of something...

PDE5I in LUTS – how do they work – no proof yet

Phosphodiesterase type 5 (PDE5) inhibitors used in erectile dysfunction (ED) have been shown to improve lower urinary tract symptoms (LUTS) as well. The mechanism is not well understood. One of the hypotheses for benign prostatic hyperplasia (BPH) – LUTS is...

Tolerability and persistence in women prescribed mirabegron

Mirabegron is a beta-3 agonist used in the treatment of overactive bladder (OAB). Trials have shown reduced side-effects but equal efficacy when compared to anticholinergics. The authors wished to examine patients’ persistence with treatment, in a non-trial setting, over a...

New therapy for overactive bladder

Overactive bladder (OAB) is a complex symptom that can adversely affect quality of life. So far pharmacotherapy has focused on anti-cholinergic drugs. Recently, beta-adrenoreceptors have been identified as having an effect on the detrusor muscle and urothelium. Beta-3 is the...